Gynecologic Oncology Reports最新文献

{"title":"Information needs during cancer care: qualitative research with advanced cervical cancer patients in Brazil, China, Germany, and the United States","authors":"Elizabeth A. Szamreta ,&nbsp;Graceanne R. Wayser ,&nbsp;Vimalanand S Prabhu ,&nbsp;Emily Mulvihill ,&nbsp;Katherine Aguinaga ,&nbsp;Ritu Salani","doi":"10.1016/j.gore.2022.101131","DOIUrl":"10.1016/j.gore.2022.101131","url":null,"abstract":"<div><h3>Objective</h3><div>Information needs for advanced cervical cancer patients have not been well studied. Our aim was to understand key drivers and barriers to seeking information, the best means of information delivery, and how this information affects the patient’s treatment experience.</div></div><div><h3>Methods</h3><div>This was a qualitative study among international cohorts to assess the information needs of adult patients diagnosed with persistent, recurrent, or metastatic cervical cancer. Semi-structured interviews were held with patients of diverse demographic and socioeconomic backgrounds within two years of obtaining their cancer diagnosis. NVivo qualitative analysis software was used to identify themes that emerged from the data.</div></div><div><h3>Results</h3><div>In 2021, we interviewed 98 patients from Brazil (n = 25), China (n = 25), Germany (n = 20), and the United States (US) (n = 28) with a mean age ranging from 38.6 to 54.2 years. Becoming aware of treatment options and understanding prognosis were key motivators for seeking cervical cancer information. This information made patients feel more informed and confident in their care. Physicians were the preferred distributor of information due to their credibility and ability to only share information pertinent to the patient’s specific stage and type of cancer. The primary challenges for seeking information were finding trustworthy resources, feeling overwhelmed with negative information, and understanding the content and relevance to their diagnosis.</div></div><div><h3>Conclusions</h3><div>There is an unmet need for readily-found information on advanced cervical cancer that is credible, easy to understand, individualized, and stage-specific. Providing patients with this information could help them achieve a more satisfying treatment experience.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 101131"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44130771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gynecologic oncology education for obstetrics and gynecology residents: a needs assessment","authors":"Cecilia Rossi,&nbsp;Graham Chapman,&nbsp;Allison Reid,&nbsp;Lindsay Ferguson,&nbsp;Amy Armstrong","doi":"10.1016/j.gore.2026.102036","DOIUrl":"10.1016/j.gore.2026.102036","url":null,"abstract":"<div><h3>Objective</h3><div>The objective of this needs assessment is to determine self-identified areas of strength and weakness in residents’ Gynecologic Oncology (GO) knowledge and elucidate gaps that may be addressed in future curricular initiatives.</div></div><div><h3>Design</h3><div>This was a cross-sectional survey designed to assess the effectiveness of current GO curricula at residency programs across the United States. Needs assessment surveys were distributed via a Program Director (PD) listserv to Obstetrics and Gynecology (OB/GYN) PDs in May 2024, with requests to distribute to OB/GYN residents and GO faculty. The primary outcome in this study was respondents’ overall satisfaction with their current GO curricula. Groups were compared in a pairwise fashion using Chi-squared testing for categorical variables and <em>t</em> test or Wilcoxon rank sum for continuous parametric and non-parametric variables, respectively. Multivariate logistic regression was used to control for confounders and to identify variables that were independently associated with participant satisfaction. As a secondary outcome, respondent scores assigned to ten key topics within GO were ranked.</div></div><div><h3>Results</h3><div>There were 85 survey respondents including 51 residents and 34 faculty. The primary composite outcome of satisfaction with the current curriculum was met in 30 participants (35.3%). Those who were satisfied were more likely to be part of a large residency program (43.3% vs 20.0%, p = 0.02), and reported greater numbers of annual gynecologic oncology lectures (5 + lectures, 70.0% vs 30.9%, p=&lt;0.001). No difference was noted between groups in regard to region or setting of residency program, gender, or rate of additional graduate degrees. Satisfaction was reported in 27.4% of residents vs 47.1% of faculty (p = 0.06).On multivariate logistic regression, having 5 or more lectures per year was the only independent predictor of higher satisfaction (aOR 4.8, 95%CI 1.7–13.4, p = 0.003). Both residents and faculty reported the strongest resident knowledge was in the following 3 key domains: preoperative and postoperative care, critical care and inpatient management, and surgical principles. Residents identified lectures as their preferred educational format, and a preference for supplemental education to be offered during protected resident education time at the workplace.</div></div><div><h3>Conclusions</h3><div>In this survey study we aimed to assess the overall levels of satisfaction with GO educational curricula, to identify specific areas of strengths and weaknesses within curricula, and to propose strategies for improvement. Satisfaction rates with GO curricula amongst current OBGYN residents and faculty were relatively low. Our findings suggest that investing in GO-focused lectures may improve resident education curricula.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102036"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A web-based application to promote palliative care in advanced ovarian cancer: A pre-post design","authors":"Susie Cho ,&nbsp;Kenneth Pike ,&nbsp;Seth Wolpin ,&nbsp;Mihkai Wickline ,&nbsp;Holly Tomashek ,&nbsp;Donna L Berry ,&nbsp;Barbara A Goff","doi":"10.1016/j.gore.2025.102015","DOIUrl":"10.1016/j.gore.2025.102015","url":null,"abstract":"<div><h3>Background</h3><div>In the advanced ovarian cancer setting (AOC), palliative care (PC) is appropriate for virtually every patient. The objectives of this study were 1) to compare referral and visit rates to PC services, pre and post implementation of the electronic Self-Assessment and Care (eSAC) application, in both a prospective study sample and for the institutional population of patients with advanced ovarian cancer; and 2) explore patients’ experiences integrating PC into their medical care.</div></div><div><h3>Methods</h3><div>Participants remotely submitted symptom and quality of life (QOL) reports about 5 days prior to clinic visits. Moderate-severe symptoms or QOL reports triggered teaching modules, including PC, and clinicians received summary reports with a PC prompt. PC rates were calculated for the prospective sample participants. Pre- and post-study rates for PC were compared using two-sample tests of proportions in the institutional population. A purposive sample of participants who triggered PC referral recommendations were recruited for semi-structured, telephone interviews to explore their experiences with PC integration. Reflexive thematic analysis was conducted to analyze interview data.</div></div><div><h3>Results</h3><div>In the prospective sample, 145/165 (88 %) patients enrolled; 120 submitted ≥1 report. 78/120 (65 %) participants triggered the PC referral recommendation on ≥1 report; 46 of 78 (59 %) were referred to PC and 49 (63 %) had an initial PC visit by six weeks after the end of the enrollment period. From pre-to-post implementation, institutional PC referral rates increased from 8.6 % to 12.8 % (p = 0.014). Rates of having a PC visit were not significant between pre- and post-implementation. Thirteen participants completed qualitative interviews. Two primary domains emerged: cancer care narratives, and perceptions of PC integration. Key barriers to PC engagement included limited understanding of PC scope, perception of adequate current care, and concerns about care burden and appointment fatigue.</div></div><div><h3>Conclusions</h3><div>Implementation of eSAC may have impacted the institutional referral rates for PC but did not result in a significant increase in visits. In study participants who triggered a referral, 63 % attended at least one PC visit. Qualitative findings revealed significant barriers to PC engagement including limited understanding of PC services and perceived care burden.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102015"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and therapeutic implications of clinical-radiologic discrepancy in parametrial invasion prior to primary radical hysterectomy in cervical cancer","authors":"Ester P. Olthof ,&nbsp;Nicholai A. Oostveen ,&nbsp;Maaike A. van der Aa ,&nbsp;Ruud L.M. Bekkers ,&nbsp;Constantijne H. Mom ,&nbsp;Jacobus van der Velden ,&nbsp;Joost Nederend ,&nbsp;Edith M.G. van Esch","doi":"10.1016/j.gore.2025.102002","DOIUrl":"10.1016/j.gore.2025.102002","url":null,"abstract":"<div><h3>Aim</h3><div>This study evaluates the prognostic and therapeutic implications of clinical-radiologic discrepancy in parametrial invasion of cervical cancer prior to radical hysterectomy. We compared patients with radiological presence but clinical absence of parametrial invasion (discrepancy group) to those without radiologic and clinical suspicion of parametrial invasion (consensus group).</div></div><div><h3>Methods</h3><div>Women with International Federation of Gynaecology and Obstetrics (2009) stage IA-IIA cervical cancer, diagnosed between 2009 and 2017, who underwent magnetic resonance imaging prior to radical hysterectomy were retrospectively selected from the Netherlands Cancer Registry. Kaplan-Meier estimates and Cox proportional hazards were used for survival and logistic regression for risk of adjuvant therapy and toxicity.</div></div><div><h3>Results</h3><div>Of 886 patients included, 87 (10%) had clinical-radiologic parametrial invasion discrepancy. Patients with discrepancy were more likely to have poor prognostic factors (i.e., a larger tumor, increased depth of invasion, lymphovascular space invasion, nodal metastases and positive resection margins) than those without. The 5-year disease-free and overall survival rates were lower in the discrepancy (74% and 82%) than in the consensus group (86% and 92%). However, after confounder adjustments, disease-free and overall survival were not affected by clinical-radiologic discrepancy. Patients with discrepancy in parametrial invasion were more likely to receive adjuvant therapy (54% vs 23%) and experience therapy-related toxicity (44% vs 29%).</div></div><div><h3>Conclusion</h3><div>Clinical-radiologic discrepancy of parametrial invasion occurs in approximately 10% of patients and is associated with poor prognostic factors and increased likelihood of adjuvant therapy and toxicity. This highlights the importance of addressing these factors in treatment counselling for either primary chemoradiotherapy or surgery.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102002"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145788035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment delay and prolongation in locally advanced cervical cancer","authors":"Maya Gross ,&nbsp;Joyce Y. Wang ,&nbsp;Barbara A. Goff ,&nbsp;Ting Martin Ma ,&nbsp;Kylie H. Kang ,&nbsp;Kemi M. Doll ,&nbsp;Soledad Jorge","doi":"10.1016/j.gore.2025.102004","DOIUrl":"10.1016/j.gore.2025.102004","url":null,"abstract":"<div><h3>Objectives</h3><div>Prolonged chemoradiation (CRT) duration predicts inferior survival in locally advanced cervical cancer (LACC). Pre-treatment delays and causes of prolonged treatment duration are less characterized. We aimed to quantify delays across the care continuum and identify predictors of delayed CRT initiation and treatment prolongation.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, we evaluated LACC patients receiving definitive CRT from 2013 to 2024 at an NCI-designated Cancer Center. We assessed care intervals and sociodemographic/clinical variables. Primary outcome was total patient delay (diagnosis to CRT completion), subdivided into delayed treatment initiation (&gt;75th percentile from diagnosis to CRT) and prolonged CRT duration (&gt;56 days). Secondary outcomes included predictors of delay / prolongation (x<strong>²</strong> tests, logistic regression), progression free survival (PFS), and overall survival (OS).</div></div><div><h3>Results</h3><div>Among 92 patients, median time to CRT initiation was 49 days (IQR 40–62) and median treatment duration was 57 days (IQR 52–60). Treatment delay or prolongation was associated with insurance type, external beam radiation therapy (EBRT) at an outside facility, and adenocarcinoma histology (p &lt; 0.05). Time from diagnosis to completion of LACC staging was the interval most predictive of treatment delay (OR 3.7, CI 1.8–7.7). Treatment prolongation was associated with longer intervals between EBRT and brachytherapy (BT) (OR 2.6,CI 1.6–4.2) but not with time to initiate EBRT or EBRT duration. PFS and OS were not associated with primary outcomes.</div></div><div><h3>Conclusions</h3><div>A quarter of patients waited over 2 months to initiate CRT, and half experienced prolonged treatment duration. Delays in staging and transitions in care, especially between institutions, contributed significantly to total patient delay.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102004"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab and SBRT for vaginal cuff recurrence of endometrial carcinoma with regression beyond the radiation field","authors":"Maria Fazal ,&nbsp;Serena Mao ,&nbsp;Deborah Armstrong ,&nbsp;Akila N. Viswanathan","doi":"10.1016/j.gore.2025.102010","DOIUrl":"10.1016/j.gore.2025.102010","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102010"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing long-term quality of life and survivorship priorities in cervical cancer patients: a social media survey-based study","authors":"Edward A. Joseph ,&nbsp;Manasa Mula ,&nbsp;Muhammad Muntazir Mehdi Khan ,&nbsp;Casey J. Allen","doi":"10.1016/j.gore.2026.102031","DOIUrl":"10.1016/j.gore.2026.102031","url":null,"abstract":"<div><h3>Background</h3><div>We evaluated quality of life (QOL) and healthcare priorities among cervical cancer survivors.</div></div><div><h3>Methods</h3><div>We utilized the validated Short Form 12 (SF-12) survey to assess QOL (focusing on physical [P-QOL] and mental well-being [M-QOL]) and care prioritization among cervical cancer patients. Respondents were asked how they prioritize the following healthcare priorities: overall survival (OS), emotional well-being (EWB), functional independence (FI), cost of healthcare (CC), and treatment experience (TE). Kendall’s coefficient of concordance (W) assessed agreement among respondents.</div></div><div><h3>Results</h3><div>We received 100 survey respondents, they were 45.5 ± 13.8 years old and 88% White. The most common diagnoses included squamous cell carcinoma (57.0%) and adenocarcinoma (23.0%). With moderate consensus (W = 0.340, p &lt; 0.001), patients considered OS (1.93 ± 1.26) the most important healthcare priority, followed by FI (2.63 ± 1.11) and EWB (2.76 ± 1.10). Patients attributed the lowest rank to TE (3.23 ± 1.17) and CC (4.41 ± 1.15). Patients who received chemotherapy were more likely to rank FI (2.59 ± 1.05 chemotherapy vs 2.72 ± 1.28 no chemotherapy, p = 0.620) above EWB (2.80 ± 1.09 chemotherapy vs 2.63 ± 1.15 no chemotherapy, p = 0.528). Respondents who underwent surgery reported better P-QOL (46.94 ± 12.64 vs. 37.57 ± 11.63, p &lt; 0.001) compared to non-surgically managed patients. Both M-QOL and P-QOL did not vary significantly throughout survivorship (P-QOL: 40.61 ± 12.76 at &lt; 1 year vs 35.43 ± 12.57 at &gt; 5 years, p = 0.200; M-QOL: 35.74 ± 13.65 at &lt; 1 year vs 39.55 ± 17.74 at &gt; 5 years; p = 0.637), and remained below that of the general population (p &lt; 0.050).</div></div><div><h3>Conclusions</h3><div>Cervical cancer survivors experience persistent deficits in both physical and mental well-being and consistently prioritized OS and FI, and less frequently cost considerations. This study emphasizes the importance of personalized survivorship care that evolves with patients’ changing priorities.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102031"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From #cervicalcancerscreening to #LEEP – Quality and accuracy of cervical cancer content on TikTok","authors":"Harriet Rothschild,&nbsp;Kelsey Keverline,&nbsp;Sara McKinney,&nbsp;Maureen Farrell,&nbsp;Minhazur Sarker","doi":"10.1016/j.gore.2025.102018","DOIUrl":"10.1016/j.gore.2025.102018","url":null,"abstract":"<div><h3>Objectives</h3><div>Many reproductive-aged individuals use social media platforms to gather medical advice or find community. TikTok is one of the fastest growing social media platforms and used by many reproductive-aged individuals.</div></div><div><h3>Methods</h3><div>We evaluated the top 100 English-language videos on cervical cancer screening and dysplasia treatment for relevance to the hashtag and content quality and accuracy.</div></div><div><h3>Results</h3><div>Among the included videos, most of the content highlighted patients’ personal experiences and provided little medical educational value. Notably, the videos created by medical professionals were higher quality and more often contained accurate health information.</div></div><div><h3>Conclusions</h3><div>This study highlights the need to increase content quality on TikTok to raise awareness and uptake for cervical cancer screening and treatment in reproductive-aged individuals.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102018"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies","authors":"Minyoung Jang,&nbsp;Stefan Gysler,&nbsp;Nawar A. Latif,&nbsp;Emily M. Ko,&nbsp;Robert L. Giuntoli II,&nbsp;Sarah H. Kim,&nbsp;Fiona Simpkins,&nbsp;Dimitrios Nasioudis","doi":"10.1016/j.gore.2025.102008","DOIUrl":"10.1016/j.gore.2025.102008","url":null,"abstract":"<div><h3>Objective</h3><div>Mucinous ovarian carcinoma (MOC) is a rare histologic subtype of ovarian cancer. While prognosis of early stage disease is excellent, novel treatment options are needed for advanced stage and recurrent MOC, which are associated with poor oncologic outcomes. In this context, we aimed to investigate the genomic profile of MOC and characterize the prevalence of actionable genomic alterations.</div></div><div><h3>Methods</h3><div>The American Association of Cancer Research Genomics Evidence of Neoplasia Information Exchange was accessed, and patients with mucinous ovarian, appendiceal and colorectal carcinoma were identified. Data from the OncoKB database, as provided by cBioPortal, were utilized to determine the presence of pathogenic gene alterations. When comparing the genomic profile of mucinous ovarian and colorectal or appendiceal carcinoma, to decrease the false discovery rate, a q-value of &lt; 0.05 as derived from the Benjamini-Hochberg FDR correction procedure was deemed statistically significant.</div></div><div><h3>Results</h3><div>A total of 148 patients with MOC contributing to 157 tumor samples were identified. The most commonly observed genetic alterations were in <em>KRAS</em> (69.4 %), <em>TP53</em> (64.3 %), <em>CDKN2A</em> (33.3 %), <em>CDKN2B</em> (24 %), <em>ERBB2</em> (12 %), <em>PIK3CA</em> (9.6 %), and <em>ARID1A</em> (9.0 %). <em>BRCA1</em> (0 %) and <em>BRCA2</em> (2.3 %) mutations were rare. Homologous deletion of chromosome 9p21.3 was present in 34.4 % of patients. Compared to mucinous appendiceal carcinoma (n = 268), MOC is characterized by a higher incidence of <em>TP53</em>, <em>CDKN2A</em>, <em>CDKN2B</em>, and <em>ERBB2</em> and a lower rate of <em>GNAS</em> gene alterations (q &lt; 0.001). Compared to colorectal mucinous adenocarcinoma (n = 358), MOC is characterized by a higher incidence of <em>KRAS</em>, <em>TP53</em>, <em>CDKN2A</em>, <em>CDKN2B</em>, and <em>ERBB2</em> and a lower rate of <em>PIK3CA</em>, <em>KMT2D</em>, <em>SMAD4</em>, <em>BRAF</em>, and <em>APC</em> gene alterations (q &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>MOC has a distinct genomic profile with molecular vulnerabilities that can be exploited using novel targeted therapies. Participation of patients with MOC in molecularly driven early phase basket trials should be encouraged.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102008"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stage I placental site trophoblastic tumor with complete response after pembrolizumab","authors":"Pierre Descargues ,&nbsp;Lua R. Eiriksson ,&nbsp;Pascal Rousset ,&nbsp;Adrien Msika ,&nbsp;Benoit You ,&nbsp;Alexis Trecourt ,&nbsp;Jerome Massardier ,&nbsp;Touria Hajri ,&nbsp;Bruno Borghese ,&nbsp;François Golfier ,&nbsp;Pierre-Adrien Bolze ,&nbsp;Jérôme Alexandre","doi":"10.1016/j.gore.2026.102023","DOIUrl":"10.1016/j.gore.2026.102023","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102023"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}